Janney Montgomery Scott LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Janney Montgomery Scott LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,849 shares of the specialty pharmaceutical company’s stock, valued at approximately $211,000.

Other hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the last quarter. GAMMA Investing LLC boosted its position in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares during the period. Assetmark Inc. grew its holdings in Supernus Pharmaceuticals by 2.8% in the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after acquiring an additional 908 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Supernus Pharmaceuticals by 6.2% in the third quarter. QRG Capital Management Inc. now owns 16,801 shares of the specialty pharmaceutical company’s stock valued at $524,000 after acquiring an additional 986 shares during the period. Finally, Stifel Financial Corp raised its stake in shares of Supernus Pharmaceuticals by 1.6% during the third quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after acquiring an additional 1,093 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They set an “overweight” rating and a $57.00 target price for the company.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $38.99 on Thursday. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market capitalization of $2.15 billion, a P/E ratio of 36.44 and a beta of 0.90. The company’s 50-day moving average is $37.45 and its 200 day moving average is $34.98.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.